Association of APOE4 genotype and treatment with cognitive outcomes in breast cancer survivors over time

This prospective longitudinal study of breast cancer survivors (n = 167) examined the association of apolipoprotein ε4 (APOE ε4) genotype with cognition and interactions with chemotherapy or endocrine therapy up to 6 years after treatment. In general, we found no effects of ε4 across timepoints and...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Dyk, Kathleen, Crespi, Catherine M., Bower, Julienne E., Carroll, Judith E., Petersen, Laura, Ganz, Patricia A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417038/
https://www.ncbi.nlm.nih.gov/pubmed/34480030
http://dx.doi.org/10.1038/s41523-021-00327-4
Descripción
Sumario:This prospective longitudinal study of breast cancer survivors (n = 167) examined the association of apolipoprotein ε4 (APOE ε4) genotype with cognition and interactions with chemotherapy or endocrine therapy up to 6 years after treatment. In general, we found no effects of ε4 across timepoints and treatment exposures; post hoc analysis at 3–6 years suggested a trend towards worse cognition in the domains of attention and learning among ε4 carriers exposed to endocrine therapy. Further study is needed.

Ejemplares similares